MétaCan
Menu
← Back to cohort
Record W4397044465 · doi:10.1681/asn.20233411s1854c

Effects of Ertugliflozin by Uric Acid Quintile: Observations from VERTIS CV

2023· article· en· W4397044465 on OpenAlexaff
Vikas S. Sridhar, Francesco Cosentino, Samuel Dagogo‐Jack, Richard E. Pratley, Nilo B. Cater, Margaret Noyes Essex, Mario Maldonado, Yujie Zhao, David Z.I. Cherney

Bibliographic record

VenueJournal of the American Society of Nephrology · 2023
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsUniversity of TorontoUniversity Health Network
Fundersnot available
KeywordsUric acidMedicineInternal medicineGout

Abstract

fetched live from OpenAlex

Background: The sodium-glucose cotransporter 2 inhibitor ertugliflozin (ERTU) lowers serum uric acid (UA) levels. Using data from the VERTIS CV trial (NCT01986881), the impact of ERTU on eGFR and albuminuria was investigated in patients by baseline serum UA levels. Methods: Patients with type 2 diabetes and atherosclerotic cardiovascular disease were randomized (1:1:1) to ERTU 5 mg, 15 mg (doses pooled for analyses), and placebo (PBO). Patients were categorized by baseline UA quintile (Table). UA over time, eGFR slopes (chronic from Weeks 6 to 260), and the time to first event of progression of albuminuria were analyzed for ERTU versus PBO. Results: At baseline, there were notable differences by UA subgroup, such as sex, UACR, eGFR and diuretic use (Table). ERTU was associated with reductions in UA over time in all baseline UA subgroups (Fig. A). Treatment with ERTU resulted in a significantly slower rate of yearly eGFR decline in all UA subgroups compared with PBO (P<0.001; Fig. B). ERTU was associated with a reduced risk of albuminuria progression in all UA subgroups compared with PBO (Fig. C; Pinteraction=0.34). Conclusions: In VERTIS CV, ERTU reduced UA while attenuating eGFR decline and albuminuria progression, irrespective of baseline UA quintile. Funding: Commercial Support - The study and this analysis were funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, in collaboration with Pfizer Inc., New York, NY, USA. Medical writing and/or editorial assistance was provided by Moamen Hammad, PhD, and Melissa Ward, BA, both of Scion, London, UK. This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and Pfizer Inc., New York, NY, USA. Table. - Demographic and clinical characteristics by uric acid (UA) quintile (Q) Variable Q1, UA ≤4.3 mg/dl Q2, UA >4.3 to 5.1 mg/dl Q3, UA >5.1 to 5.8 mg/dl Q4, UA >5.8 to 6.9 mg/dl Q5, UA >6.9 mg/dl N (%) 1,685 (20.5) 1,721 (21.0) 1,540 (18.8) 1,716 (20.9) 1,551 (18.9) Female, n (%) 646 (38.3) 565 (32.8) 441 (28.6) 460 (26.8) 356 (23.0) Mean age, years (SD) 63.4 (7.8) 64.1 (8.1) 64.6 (8.2) 64.7 (8.1) 65.1 (8.0) Mean body mass index, kg/m2 (SD) 30.6 (4.9) 31.3 (5.2) 31.9 (5.2) 32.2 (5.2) 33.5 (6.0) Mean glycated hemoglobin, % (SD) 8.5 (1.0) 8.3 (1.0) 8.2 (0.9) 8.1 (1.0) 8.1 (0.9) Median UACR, mg/g (range) 16.0 (1.0-7,239.0) 16.0 (1.0-5,357.0) 17.0 (1.0-6,884.0) 21.0 (1.0-8,584.0) 28.5 (1.0-9,548.0) Mean eGFR, ml/min/1.73 m2 (SD) 86.2 (15.7) 82.1 (16.6) 78.3 (17.5) 73.9 (18.2) 64.9 (18.9) Antihypertensive use, n (%) 1,567 (93.0) 1,619 (94.1) 1,465 (95.1) 1,655 (96.4) 1,516 (97.7) Diuretic use, n (%) 498 (29.6) 609 (35.4) 634 (41.2) 811 (47.3) 982 (63.3) eGFR, estimated glomerular filtration rate; Q, quintile; SD, standard deviation; UA, uric acid; UACR, urinary albumin-to-creatinine ratio.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.013

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.005
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0010.000
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.255
Teacher spread0.242 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of Nephrology→Same topicDiabetes Treatment and Management→French-language works237,207→